M42 and ArceraPartner to Advance Biopharma Localization and Next Generation Life Sciences in Abu Dhabi
Abu Dhabi, UAE – June03, 2026: M42, a global health leader powered by technology, artificial intelligence, and genomics, andArcera Life Sciences (“Arcera”), a global life sciences company focused on advancing innovative and sustainable healthcare solutions, havesigned a Memorandum of Understanding (MoU) to formalize a strategic, non-exclusive collaboration focused on advancing biopharma localization, clinical developmentand next-generation healthcare innovation in Abu Dhabi.
Aligned with the Department of Health – Abu Dhabi’s (DoH)efforts to reinforce the Emirate’s position as a global hub for life sciences innovation, the collaboration will contribute tothe development of an integrated life sciences ecosystem spanning clinical development and innovative therapeutics, addressing genetic and rare diseases with scalable treatments.
Under the collaboration, Arcera will work with M42 to leverage genomics data and query the genomics database to assess disease prevalence across specific genetic and rare diseases. Combining genomics insights enabled by DoH, alongside M42’s advanced data platforms and healthcare delivery capabilities, with Arcera’s expertise in late-stage drug development, business development, and market access, the collaboration aims to accelerate the introduction of innovative therapies and improve patient access to advanced treatment solutions in the region.The collaboration will deliver on four strategic pillars:
- Genomics-informed therapeutic development: Leveraging genomic insights generated through DoH-supported national health and research programs, alongside M42’s data platforms and Arcera’slate-stage development expertise to advance precision medicine and next-generation therapies, including cell and gene therapies.
- Clinical developmentacceleration: Supporting late-phase clinical trials, strengthening evidence generation and expanding patient access to innovative treatments
- Advanced biobanking, development of stem cell therapies and regenerative medicine: Drawing on capabilities such as Abu Dhabi Biobank to enable breakthrough therapeutic innovation
- Digital and AI-enabled transformation: Embedding innovative technologies across the life sciences value chain to enhance development efficiency and reinforce Abu Dhabi’s leadership in AI-driven healthcare
Together, these pillars are intended to support both immediate collaboration opportunities and long-term capability building across Abu Dhabi’s health and life sciences ecosystem.
Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH): “We welcome this collaboration as a reflection of the Emirate’s growing life sciences capabilities and its ambition to become a global hub for health innovation. Through its work to advance regulation, health data infrastructure, genomics insights and clinical research, DoH is helping create the conditions for partners to accelerate biopharma development, strengthen evidence generation and support the future development of treatments for genetic and rare diseases.”
Dr Fahad Al Marzooqi, Chief Executive Officer, M42 Integrated Health Solutions, said:
“This partnership with Arcera reflects M42’s strategic role in strengthening Abu Dhabi’s life sciences ecosystem through targeted, high-impact partnerships. By combining our capabilities in AI and healthcare delivery with Arcera’s expertise, we are supporting the advancement of biopharma capabilities in the Emirate, expanding clinical development opportunities and enabling the effective translation of innovation into patient care.”
Through the collaboration, M42 and Arcera will establish a framework for evaluating joint opportunities, identifying priority use cases and enabling collaboration across development and commercialization. The partnership is designed to support practical pathways for implementation while building long-term capability within Abu Dhabi’s life sciences ecosystem.
Isabel Afonso, Chief Executive Officer, Arcera Life Sciences, said:“This collaboration between two Abu Dhabi–based life sciences companies reflects the strength of the national ecosystem, bringing together innovation, manufacturing, and patient access to deliver sustainable patient impact”
By advancing biopharma localization, strengthening clinical developmentcapabilities and supporting AI- and genomics-informedinnovation, the collaboration marks an important step in the UAE’s life sciences agenda. It further reinforces M42’s role as a research excellence engine and implementation partner at scale, Arcera’s position as a late-stage drug development, regulatory, manufacturing and commercialization partner, and Abu Dhabi’s standing as an integrated health innovation ecosystem for the future.
-ENDS-
About M42
M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combinesits specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally.
Established in 2023, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers, including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.
About Arcera Life Sciences
Arcera Life Sciences is a global life sciences company headquartered in Abu Dhabi, United Arab Emirates. Our purpose is to enable longer and healthier lives while creating sustainable growth. We develop, manufacture, and commercialize a broad range of innovative and proven medicines in key international markets. With a large footprint reaching patients in over 90 markets, and manufacturing and packaging facilities in eight countries, we offer more than 2,000 medicines across various therapeutic areas worldwide. Arcera was established by ADQ, an active sovereign investor with a focus on critical infrastructure and global supply chains, to realize Abu Dhabi’s ambition as a global leader in innovative and sustainable healthcare.
To learn more about Arcera, visit http://www.arceralifesciences.com.
For media inquiries or interview opportunities, please contact:
Mazar Masud
Senior Director, Global Corporate Communications, M42
E: mmasud@m42.ae
M: +971 52 593 5926
Asala Fadda
Senior Manager, Marketing & Communications, M42
E: afadda@m42.ae
M: +971 509555076
Arcera Life Sciences
Patrick Kerr, VP Corporate Communications: patrick.kerr@arceralifesciences.comor media@arceralifesciences.com